Aduhelm: Ser o...no ser, lo aclara el ICER

 

 

 In summary, we judge that the evidence is insufficient to conclude that the clinical benefits of aducanumab outweigh its harms or, indeed, that it reduces progression of AD.

 Ver:

Aduhelm (Biogen): LOWN Institute vs FDA

 

If blended efficacy results are used from the Phase III trials, our base-case analyses suggest that an annual cost of $50,000 for aducanumab, as has been suggested by market analysts, would not be in alignment with its clinical benefits.

 

 If aducanumab were determined to have no net health benefit, no threshold price could be generated to guide considerations of fair pricing. Más
 

Ver también:

Alzheimer's drug approval: Advocacy group calls for FDA resignations